Hereditary gastrointestinal stromal tumors sharing the <i>KIT</i> Exon 17 germline mutation p.Asp820Tyr develop through different cytogenetic progression pathways

Isabel Veiga(Instituto Português de Oncologia Francisco Gentil), Manuel R. Teixeira(Instituto Português de Oncologia Francisco Gentil), Mara Silva(Instituto Português de Oncologia Francisco Gentil), Marta Soares(Instituto Português de Oncologia Francisco Gentil), Manuela Pinheiro(Instituto Português de Oncologia Francisco Gentil), José Dinis(Instituto Português de Oncologia Francisco Gentil), Carla Pinto(Instituto Português de Oncologia Francisco Gentil), Carlos Lopes(Universidade do Porto), Hugo Duarte(Instituto Português de Oncologia Francisco Gentil), Lurdes Torres(Instituto Português de Oncologia Francisco Gentil), Lúcio Lara Santos(IPO Porto), C. Coutinho(Hospital da Senhora da Oliveira Guimarães), Joana Vieira(Instituto Português de Oncologia Francisco Gentil)
Genes Chromosomes and Cancer
October 21, 2009
10.1002/gcc.20720
Cited by 16

Related Papers

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
|European Urology|2014|253
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
|European Urology|2019|244
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
|Journal of Clinical Oncology|2011|221
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
|The Lancet Oncology|2021|93